Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore

• US 5,916,910 A
• Filed: 06/04/1997
• Issued: 06/29/1999
• Est. Priority Date: 06/04/1997
• Status: Expired due to Fees

• Current Assignee: Medinox, Inc.
• Original Assignee: Medinox, Inc.
• Inventors: Lai, Ching-San
• Primary Examiner(s): NORTHINGTON DAVIS, ZINNA
• Application Number:
  US08/869,158
• Time in Patent Office: 755 Days
• Field of Search: 514/514, 514/423, 548/565, 548/573, 558/235
• US Class Current: 514/423
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07C 333/16 Salts of dithiocarbamic acids

Abstract

In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or "DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

Claims

1. A compound comprising a dithiocarbamate-containing nitric oxide scavenger attached to a pharmacologically active agent via a covalent linkage, wherein said covalent linkage is cleavable under physiological conditions;

and wherein the dithiocarbamate component of said compound has the structure I, as follows;

space="preserve" listing-type="equation"> R.sub.1 R.sub.2 N--C(S)S!.sub.x M.sup.+1,+2,+3 (I)

wherein

each of R₁ and R₂ is independently selected from a C₁ up to C₁₈ alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, alkenyl, substituted alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, aroyl, substituted aroyl, acyl, substituted acyl, or

R₁ and R₂ can cooperate to form a 5-, 6- or 7-membered ring including N, R₁, and R₂, or

R₁ or R₂ is a divalent moiety selected from the group consisting of alkylene, substituted alkylene, oxyalkylene, substituted oxyalkylene, alkenylene, and substituted alkenylene, wherein said divalent moiety serves as the same substituent for two dithiocarbamate structures, thereby linking said structures together so as to form a bis(dithiocarbamate) species,

wherein R₁ and/or R₂ further contain a site for said covalent attachment,

x is 1 or 2, and

M is a monovalent cation when x is 1, or M is a physiologically compatible divalent or trivalent transition metal cation when x is 2.

2. A compound according to claim 1 wherein:

each of R₁ and R₂ =a C₁ up to C₁₂ alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl or substituted alkynyl, wherein the substituents are selected from carboxyl, --C(O)H, oxyacyl, phenol, phenoxy, pyridinyl, pyrrolidinyl, amino, amido, hydroxy, nitro or sulfuryl, or

R₁ and R₂ cooperate to form a 5-, 6- or 7-membered ring including N, R₁ and R₂, and

M=Fe⁺² or Fe⁺³.

3. A compound according to claim 1 wherein:

R₁ is selected from a C₂ up to C₈ alkyl or substituted alkyl, wherein the substituents are selected from carboxyl, acetyl, pyridinyl, pyrrolidinyl, amino, amido, hydroxy or nitro, and

R₂ is selected from a C₁ up to C₆ alkyl or substituted alkyl, or

R₂ cooperates with R₁ to form a 5-, 6- or 7-membered ring including N, R₂ and R₁, and

M=Fe⁺².

4. A compound according to claim 1 wherein:

R₁ is selected from a C₂ up to C₈ alkyl or substituted alkyl, wherein the substituents are selected from carboxyl, acetyl, amido or hydroxy, and

R₂ is selected from a C₁ up to C₄ alkyl or substituted alkyl, or

R₂ cooperates with R₁ to form a 5- or 6-membered ring including N, R₂ and R₁, and

M=Fe⁺².

5. A compound according to claim 1 wherein said dithiocarbamate moiety is sarcosine dithiocarbamate, iminodiacetic acid dithiocarbamate, diethyldithiocarbamate, diisopropyldithiocarbamate, sugar-linked dithiocarbamates, pyrrolidine dithiocarbamate or proline dithiocarbamate.

6. A compound according to claim 1 wherein R₁ and R₂ of said dithiocarbamate moiety cooperate to form a 5- or 6-membered ring including N, R₁ and R₂.

7. A compound according to claim 6 wherein said dithiocarbamate moiety is pyrrolidine dithiocarbamate or proline dithiocarbamate.

8. A compound according to claim 6 wherein said dithiocarbamate component of said compound is L-proline dithiocarbamate.

9. A compound according to claim 1 wherein said covalent linkage is selected from the group consisting of ester linkages, disulfide linkages, amide linkages, ether linkages, thioether linkages, imide linkages, sulfate ester linkages, sulfonate ester linkages, phosphate ester linkages, carbonate linkages, O-glycosidic linkages and S-glycosidic linkages.

10. A compound according to claim 1 wherein said covalent linkage is an ester linkage.

11. A compound according to claim 1 wherein said covalent linkage is a disulfide linkage.

12. A compound according to claim 1 wherein said covalent linkage is an amide linkage.

13. A compound according to claim 1 wherein said covalent linkage is a sulfonate ester linkage.

14. A compound according to claim 1 wherein said covalent linkage is a sulfate ester linkage.

15. A compound according to claim 1 wherein said covalent linkage is a phosphate ester linkage.

16. A compound according to claim 1 wherein said pharmacologically active agent is selected from NSAIDs, analgesics/antipyretics, sedatives/hypnotics, antianginal agents, antianxiety agents, antidepressants, antipsychotic agents, antimanic agents, antiarrhythmics, antihypertensive drugs, antihistamine/antipruritic drugs, immunosuppressants, antimetabolite cytotoxics, neuroprotective agents, T cell inhibitors, antimigraine agents, antiarthritic agents, antigout agents, anticoagulants, thrombolytic agents, antifibrinolytic agents, hemorheologic agents, antiplatelet agents, anticonvulsants, agents useful for calcium regulation, antibacterial agents, antifungal agents, antiviral agents, antimicrobials, anti-infectives, bronchodialators, hormones, hypoglycemic agents, hypolipidemic agents, proteins, nucleic acids, agents useful for erythropoiesis stimulation, antiulcer/antireflux agents, antinauseants/antiemetics, septic shock agents, multiple sclerosis agents, organ transplantation agents, systemic lupus erythematosus (SLE) agents, Alzheimer'"'"'s disease agents, antiparkinson agents, psoriasis agents, diabetes agents, stroke agents, agents useful for the treatment of carcinomas, agents useful for the treatment of endometriosis, agents useful for the treatment of uterine contraction, agents useful for the treatment of diuresis, agents useful for the treatment of cystic fibrosis, agents useful for the treatment of neutropenia, agents useful for the treatment of lung cancer, agents useful for the treatment of respiratory disorders, agents useful for the treatment of ischemia/reperfusion injury, agents useful for the treatment of ophthalmic diseases, agents useful for the treatment of cardiovascular diseases, anti-inflammatory agents or antioxidants.

17. A compound according to claim 1 wherein said pharmacologically active agent is a non-steroidal antiflammatory drug, an antihypertensive agent, an antineoplastic agent, an anti-allograft rejection agent, a neuroprotective agent, an immunosuppressive agent or an antioxidant.

18. A compound according to claim 1 wherein said pharmacologically active agent is aspirin, ibuprofen, ketoprofen, diclofenac, adriamycin, cyclosporin, FK506, LFA-1, selectin inhibitors, tissue plasminogen activator or lubeluzole.

19. A composition comprising a compound according to claim 1 in a pharmaceutically acceptable carrier therefor.

20. A composition according to claim 19 wherein said pharmaceutically acceptable carrier is a solid, solution, emulsion, dispersion, micelle or liposome.

21. A composition according to claim 19 wherein said composition further comprises an enteric coating.

22. In the administration of a pharmacologically active agent to a subject for the treatment of a pathological condition, the improvement comprising attaching a dithiocarbamate-containing nitric oxide scavenger to said pharmacologically active agent via a covalent linkage prior to administration of said pharmacologically active agent to said subject, wherein the dithiocarbamate component of said compound has the structure I, as follows:

space="preserve" listing-type="equation"> R.sub.1 R.sub.2 N--C(S)S!.sub.x M.sup.+1,+2,+3 (I)

wherein

each of R₁ and R₂ is independently selected from a C₁ up to C₁₈ alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, alkenyl, substituted alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, aroyl, substituted aroyl, acyl, substituted acyl, or

R₁ and R₂ can cooperate to form a 5-, 6- or 7-membered ring including N, R₁, and R₂, or

R₁ or R₂ is a divalent moiety selected from the group consisting of alkylene, substituted alkylene, oxyalkylene, substituted oxyalkylene, alkenylene, and substituted alkenylene, wherein said divalent moiety serves as the same substituent for two dithiocarbamate structures, thereby linking said structures together so as to form a bis(dithiocarbamate) species,

wherein R₁ and/or R₂ further contain a site for said covalent attachment,

x is 1 or 2, and

M is a monovalent cation when x is 1, or M is a physiologically compatible divalent or trivalent transition metal cation when x is 2.

23. In the treatment of a subject suffering from a pathological condition by administration thereto of a pharmacologically active agent, the improvement comprising attaching a dithiocarbamate-containing nitric oxide scavenger to said pharmacolgically active agent via a covalent linkage prior to administration thereof to said subject, wherein the dithiocarbamate component of said compound has the structure I, as follows:

space="preserve" listing-type="equation"> R.sub.1 R.sub.2 N--C(S)S!.sub.x M.sup.+1,+2,+3 (I)

wherein

each of R₁ and R₂ is independently selected from a C₁ up to C₁₈ alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, alkenyl, substituted alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, aroyl, substituted aroyl, acyl, substituted acyl, or

R₁ and R₂ can cooperate to form a 5-, 6- or 7-membered ring including N, R₁, and R₂, or

R₁ or R₂ is a divalent moiety selected from the group consisting of alkylene, substituted alkylene, oxyalkylene, substituted oxyalkylene, alkenylene, and substituted alkenylene, wherein said divalent moiety serves as the same substituent for two dithiocarbamate structures, thereby linking said structures together so as to form a bis(dithiocarbamate) species,

wherein R₁ and/or R₂ further contain a site for said covalent attachment,

x is 1 or 2, and

M is a monovalent cation when x is 1, or M is a physiologically compatible divalent or trivalent transition metal cation when x is 2.

24. A method for the treatment of a subject afflicted with a pathological condition, said method comprising administering to said subject an effective amount of a modified pharmacologically active agent,

wherein said pharmacologically active agent is effective for treatment of said condition, and

wherein said pharmacologically active agent has been modified by the covalent attachment thereto of a dithiocarbamate-containing nitric oxide scavenger, wherein the dithiocarbamate component of said compound has the structure I, as follows:

space="preserve" listing-type="equation"> R.sub.1 R.sub.2 N--C(S)S!.sub.x M.sup.+1,+2,+3 (I)

wherein

each of R₁ and R₂ is independently selected from a C₁ up to C₁₈ alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, alkenyl, substituted alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, aroyl, substituted aroyl, acyl, substituted acyl, or

R₁ and R₂ can cooperate to form a 5-, 6- or 7-membered ring including N, R₁, and R₂, or

R₁ or R₂ is a divalent moiety selected from the group consisting of alkylene, substituted alkylene, oxyalkylene, substituted oxyalkylene, alkenylene, and substituted alkenylene, wherein said divalent moiety serves as the same substituent for two dithiocarbamate structures, thereby linking said structures together so as to form a bis(dithiocarbamate) species,

wherein R₁ and/or R₂ further contain a site for said covalent attachment,

x is 1 or 2, and

M is a monovalent cation when x is 1, or M is a physiologically compatible divalent or trivalent transition metal cation when x is 2.

25. A method for the preparation of a protected form of a pharmacologically active agent, said method comprising attaching a dithiocarbamate-containing nitric oxide scavenger to said pharmacologically active agent via a covalent linkage, wherein the dithiocarbamate component of said compound has the structure I, as follows:

space="preserve" listing-type="equation"> R.sub.1 R.sub.2 N--C(S)S!.sub.x M.sup.+1,+2,+3 (I)

wherein

each of R₁ and R₂ is independently selected from a C₁ up to C₁₈ alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, alkenyl, substituted alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, substituted alkyl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, aroyl, substituted aroyl, acyl, substituted acyl, or

R₁ and R₂ can cooperate to form a 5-, 6- or 7-membered ring including N, R₁, and R₂, or

R₁ or R₂ is a divalent moiety selected from the group consisting of alkylene, substituted alkylene, oxyalkylene, substituted oxyalkylene, alkenylene, and substituted alkenylene, wherein said divalent moiety serves as the same substituent for two dithiocarbamate structures, thereby linking said structures together so as to form a bis(dithiocarbamate) species,

wherein R₁ and/or R₂ further contain a site for said covalent attachment,

x is 1 or 2, and

M is a monovalent cation when x is 1, or M is a physiologically compatible divalent or trivalent transition metal cation when x is 2.

26. A method for reducing the side effects induced by administration of a pharmacologically active agent to a subject, said method comprising attaching a dithiocarbamate-containing nitric oxide scavenger to said pharmacologically active agent via a covalent linkage prior to administration to said subject, wherein the dithiocarbamate component of said compound has the structure I, as follows:

space="preserve" listing-type="equation"> R.sub.1 R.sub.2 N--C(S)S!.sub.x M.sup.+1,+2,+3 (I)

wherein

each of R₁ and R₂ is independently selected from a C₁ up to C₁₈ alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, alkenyl, substituted alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, aroyl, substituted aroyl, acyl, substituted acyl, or

R₁ and R₂ can cooperate to form a 5-, 6- or 7-membered ring including N, R₁, and R₂, or

R₁ and R₂ is a divalent moiety selected from the group consisting of alkylene, substituted alkylene, oxyalkylene, substituted oxyalkylene, alkenylene, and substituted alkenylene, wherein said divalent moiety serves as the same substituent for two dithiocarbamate structures, thereby linking said structures together so as to form a bis(dithiocarbamate) species,

wherein R₁ and/or R₂ further contain a site for said covalent attachment,

x is 1 or 2, and

M is a monovalent cation when x is 1, or M is a physiologically compatible divalent or trivalent transition metal cation when x is 2.

27. A method for enhancing the effectiveness of a pharmacologically active agent, said method comprising attaching a dithiocarbamate-containing nitric oxide scavenger to said pharmacologically active agent, via a covalent linkage.